News Agency
The Times

AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S.

  • Written by Media Outreach

Multiple Institutions Give AIM a "Buy" Rating

HONG KONG SAR - Media OutReach Newswire – 5 February 2025 - AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, announced today that its independently developed mRNA RSV (respiratory syncytial virus) vaccine has recently been submitted for clinical trials to the U.S. Food and Drug...

Read more: AIM Vaccine mRNA RSV Vaccine Submits for Clinical Trials in the U.S.

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion